Vaxcyte, Inc.

PCVX Healthcare Biotechnology

In the quarter to June 2026, EPS fell 61.5% and free cash flow fell 92.6%, each against the same quarter a year earlier.

63.62 1.65 −2.53%
Market cap
$10.3B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
5.72 7.49 7.91 8.83

+8 more quarters

Net Debt/EBITDA
4.99 5.06 5.84 7.15
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.64) (2.03) (1.67) (1.08)
Book value per Share
19.09 21.48 19.73 21.24
Free Cash Flow
(236.79) (282.73) (227.49) (147.13)
Other line items

Show all line items

Columns are period end dates